ELX-02

https://investors.eloxxpharma.com/news-releases/news-release-details/enrollment-us-phase-2-clinical-trial-cystic-fibrosis-has-resumed

Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 Pandemic

https://www.globenewswire.com/news-release/2020/08/04/2072353/0/en/Eloxx-Pharmaceuticals-Receives-U-S-Orphan-Drug-Designation-for-ELX-02-for-the-Treatment-of-Cystic-Fibrosis.html

Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis
ELX-02 had previously been granted orphan medicinal product designation for the treatment of Cystic Fibrosis by the European Medicines Agency

https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-announces-cystic-fibrosis-foundation-cf

Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Funding and Support for ELX-02 U.S. Phase 2 Clinical Trial

https://www.globenewswire.com/news-release/2019/03/27/1773995/0/en/Eloxx-Pharmaceuticals-Presents-Positive-New-Data-for-Lead-Investigational-Drug-ELX-02-at-the-European-Cystic-Fibrosis-Society-ECFS-Basic-Science-Conference.html

https://apnews.com/Globe%2520Newswire/0477890fdeef1e23fb57e43611e83f77